MAY 08, 2018 10:27 PM PDT

Developing a Drug For Genetic Obesity

WRITTEN BY: Nouran Amin

Researchers from the Institute for Experimental Pediatric Endocrinology of the Charité -- Universitätsmedizin Berlin have fortunately treated patients with genetic obesity using a recent developed drug.

Genetic obesity is obesity caused by a mutation in one or multiple genes that have a relation fat storage and hunger. Aside from its beneficial effects on the patients, the researchers also provided insights into the fundamental signaling pathways regulating satiety of the new drug. The results of this research were published in Nature Medicine.

In this study, a mutation in the gene encoding the leptin receptor (LEPR) leads to extreme hunger starting with the first months of life. As a result, individuals affected developed extreme obesity during childhood. However, for these cases, increased exercise and reduced caloric intake are still not relevant as well as obesity surgery. This explains why a drug-based approach remains a priority.

Furthermore, roughly two years before the study, Dr. Peter Kühnen and team demonstrated that treatment with a peptide, which works to activate the melanocortin 4 receptor (MC4R) that may have a role in energy metabolism in the body as well as body weight regulation.

Leptin, which is known as the satiety (or starvation) hormone, will normally bind to the leptin receptor (LEPR) which then leads to the production of melanocyte-stimulating hormone (MSH). However, if there exists a mutation in LEPR that leads to a functional defect then the signaling cascade is disrupted. This allows the patient's hunger to continue to be unabated, placing the individual at a high risk.

Part of this current study, investigators used a peptide that binds to the MC4R in the brain, and through this activation, it will trigger the normal satiety signal. "We also wanted to determine why the used peptide was so effective and why, in contrast to other preparations with a similar mode of action, it did not produce any severe side effects," explains Dr. Kühnen. "We were able to demonstrate that this treatment leads to the activation of a specific and important signaling pathway, whose significance had previously been underestimated." Dr. Kühnen's team is planning to conduct further research to determine whether other patients might benefit from this drug: "It is possible that other groups of patients with dysfunctions affecting the same signaling pathway might be suitable candidates for this treatment."

 

Sources: Charité - Universitätsmedizin Berlin

 

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 09, 2018
Drug Discovery
OCT 09, 2018
Weight Loss Drug Reduces Incidence of Diabetes
A clinical trial weight loss drug, by the name of Lorcaserin—manufactured by Eisai Inc., was found to reduce the risk of diabetes by 19 percent in pa...
OCT 18, 2018
Drug Discovery
OCT 18, 2018
Potential Drug Target for Tactile Allodynia
According to research published in the journal Science Translational Medicine in collaboration with a study led by the National Institutes of Health, a new...
DEC 04, 2018
Drug Discovery
DEC 04, 2018
Drug Combination May Be Effective for Melanoma
Protein kinase inhibitors have been noted to be the most effective class of drugs in the treatment of melanoma—a deadly skin cancer of the melanocyte...
DEC 15, 2018
Drug Discovery
DEC 15, 2018
Ebola-Fighting Protein Paves The Way For New Drugs
In a study published in Cell, research at Northwestern University School of Medicine has involved scientists discovering a human protein that could be...
DEC 17, 2018
Drug Discovery
DEC 17, 2018
Alzheimer Preventing Drug Could Work Like A Vaccine
Researchers at UT Southwestern believe that a protein called ApoE is the primary factor in late-onset Alzheimer's disease. Such conclusion has to inspi...
JAN 24, 2019
Drug Discovery
JAN 24, 2019
Drug Blocks Toxic-Protein Production in ALS
Individuals with ALS, frontotemporal dementia, carry a mutation in the gene C9orf72—resulting in repeated DNA sequences. These repetitions result in ...
Loading Comments...